Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-targeted DC Vaccination in AML
NCT01686334Phase 2Active, not recruiting
- Start
- Oct 2012
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in acute myeloid leukemia (AML). Started Oct 2012; status: active, not recruiting.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01686334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01686334.